Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07135882). This is a study registration, not published results. Lead sponsor: Trans Tasman Radiation Oncology Group. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 420 participants (ESTIMATED). Conditions: Carcinoma, Non-Small-Cell Lung (NSCLC). Interventions: COMBINATION_PRODUCT: Radiotherapy followed by chemotherapy; DRUG: Standard of Care (SOC). Primary outcome measures: Overall survival , 5 years after the last participant was recruited. Brief summary: Lung cancer has the highest mortality rate of all cancers in Australia and is an area of unmet need. It starts in the lung (the primary tumour), and then spreads (metastasise) to other organs. The PRIME-Lung clinical trial will investigate if radiotherapy to the primary lung tumour, in addition to standard drug therapies, for patients with metastatic lung cancer will lead to less spread of cancer, prolong life, improve patient well-being and be cost-effective for the health care system.